Bilirubin 1.40 mg/dL - Clinical Interpretation

Is It Normal?

The standard adult reference range for total bilirubin is 0.2 to 1.2 mg/dL (3-20 µmol/L). At 1.40 mg/dL, this value is mildly above the upper limit of normal - technically a mild hyperbilirubinemia. However, context matters enormously: many labs use an upper cutoff of 1.5 mg/dL, and some consider values up to 2.0 mg/dL borderline. No jaundice (visible yellowing) occurs until bilirubin reaches approximately 2.5-3.0 mg/dL.

What Does It Indicate?

The clinical significance depends on which fraction is elevated (unconjugated vs. conjugated) and whether other liver tests are abnormal.

1. Most Likely - Gilbert Syndrome (Benign)

The most common cause of mildly elevated total bilirubin in otherwise healthy individuals, affecting 3-12% of the population (higher in Middle Eastern populations)
Caused by a UGT1A1 promoter variant that reduces hepatic bilirubin conjugation by 30-50%
Bilirubin typically stays below 3 mg/dL, almost entirely unconjugated
Worsens with fasting, stress, illness, or exercise - then normalizes
No treatment needed - considered cardiovascular-protective due to antioxidant properties of bilirubin
Diagnosis: elevated indirect (unconjugated) bilirubin, normal ALT/AST/GGT/ALP, no hemolysis

2. Mild Hemolysis

Increased red cell breakdown produces more unconjugated bilirubin than the liver can process
Bilirubin rarely exceeds 4-5 mg/dL with hemolysis alone
Look for: low hemoglobin, elevated LDH, elevated reticulocyte count, low haptoglobin

3. Drug Effect

Drugs like rifampin and cyclosporine can competitively inhibit the sinusoidal transport protein OATP1B1, causing unconjugated hyperbilirubinemia
Atazanavir (HIV medication) is a well-known cause of benign indirect bilirubin elevation by inhibiting UGT1A1

4. Early or Subclinical Hepatobiliary Disease

If the conjugated (direct) fraction is elevated (>20% of total, or >0.3 mg/dL), this is more concerning and points toward:
- Hepatocellular disease (hepatitis, cirrhosis)
- Cholestasis (intrahepatic or extrahepatic)
- Dubin-Johnson or Rotor syndrome (rare, benign hereditary causes)

How to Differentiate - Key Next Steps

Test	Why
Direct vs. indirect bilirubin	Separates conjugated from unconjugated - the most important next step
ALT, AST, ALP, GGT	If all normal with indirect elevation -> strongly suggests Gilbert syndrome
CBC with reticulocyte count	Rules out hemolysis
LDH, haptoglobin	Additional hemolysis markers
Urine bilirubin	Only conjugated bilirubin appears in urine; positive urine bilirubin = hepatobiliary cause

Bottom Line

A value of 1.40 mg/dL is mildly above normal but is most likely benign, especially in an asymptomatic person with no other abnormal liver function tests. The most common explanation is Gilbert syndrome. Further fractionation (direct vs. indirect bilirubin) alongside a basic liver panel is the appropriate next step to confirm this or identify a pathological cause.

Sources: Miller's Anesthesia 10e, p. 1494-1496; Sleisenger and Fordtran's Gastrointestinal and Liver Disease, p. 336; The Washington Manual of Medical Therapeutics

Gilbert syndrome

Finding Sources

Searching PubMed

Gilbert syndrome UGT1A1 clinical review

Reading File

Finding Sources

Reading File

Here is a complete summary of Gilbert Syndrome from authoritative sources:

Gilbert Syndrome

Definition & Genetics

Gilbert syndrome is the most common hereditary cause of hyperbilirubinemia, affecting 6-12% of the general population (some sources cite 3-7% in the USA, with the highest prevalence in the Middle East and lowest in East Asia).

It is caused by a mutation in the 5' TATA box of the UGT1A1 gene promoter (the UGT1A1*28 allele - an A(TA)₂TAA homozygous polymorphism). This reduces transcription factor binding and promoter activity, resulting in 30-50% reduction in hepatic glucuronosyltransferase (UGT1A1) activity, the enzyme responsible for conjugating bilirubin for excretion.

Allele frequencies: ~42% in Black populations, ~30% in White populations, ~10% in Asian populations
In Asian populations, coding region polymorphisms are more common than the *28 allele

Pathophysiology

Reduced UGT1A1 activity → less bilirubin conjugated → accumulation of unconjugated (indirect) bilirubin in plasma. The liver architecture and all other hepatic functions remain completely normal.

Clinical Features

Feature	Detail
Presentation	Usually incidental finding on routine blood tests
Bilirubin level	≤3 mg/dL (typically 1.2-3.0 mg/dL), almost entirely unconjugated
Jaundice	Mild, intermittent scleral icterus; clinical jaundice is uncommon
Triggers	Fasting, dehydration, illness, physical stress, surgery, alcohol - causes 2-3x rise in bilirubin
Onset	Often first noticed in adolescence (sex steroids alter bilirubin metabolism)
Symptoms	Generally asymptomatic
Liver histology	Usually normal; occasional lipofuscin deposits

Diagnosis

Gilbert syndrome is a clinical/biochemical diagnosis - no biopsy needed.

Criteria:

Mild isolated unconjugated hyperbilirubinemia (indirect fraction elevated)
Normal ALT, AST, ALP, GGT
Normal CBC (no hemolysis)
No other identifiable cause
Worsens with fasting, improves with eating

Confirming tests (if needed):

Fractionated bilirubin: indirect (unconjugated) predominance
Normal urobilinogen; no bilirubinuria (unconjugated bilirubin is not water-soluble, so it does not spill into urine)
Fasting test: bilirubin rises significantly after 24-48h caloric restriction
Phenobarbital: induces UGT1A1, normalizes bilirubin - confirms the diagnosis
Genetic testing for UGT1A1*28 (not routinely needed)

Drug Interactions - Important Clinical Warning

Most drug metabolism is normal in Gilbert syndrome, but there are critical exceptions:

Irinotecan (CPT-11) - anti-cancer drug whose active metabolite SN-38 is specifically glucuronidated by UGT1A1. Patients with Gilbert syndrome are at high risk for severe toxicity: intractable diarrhea, myelosuppression. Dose reduction is often required.
Atazanavir / Indinavir (HIV protease inhibitors) - inhibit UGT1A1, causing hyperbilirubinemia in >25% of users; Gilbert syndrome patients are at even higher risk.
Raloxifene (estrogen modulator) - UGT1A1 substrate; homozygous *28 allele causes ~2x higher drug exposure.

Prognosis & Treatment

No treatment required
Normal prognosis and life expectancy
The condition is considered cardiovascular-protective - bilirubin acts as an endogenous antioxidant
Patients should be reassured it is benign
Key: inform the patient about drug interactions (especially if they may receive irinotecan)

Comparison with Related Disorders

	Gilbert	Crigler-Najjar I	Crigler-Najjar II	Dubin-Johnson	Rotor
Gene	UGT1A1	UGT1A1	UGT1A1	MRP2	OATP1B1 + 1B3
Defect	Reduced conjugation	No conjugation	Markedly reduced conjugation	Impaired canalicular export	Impaired sinusoidal reuptake
Bilirubin type	Unconjugated	Unconjugated	Unconjugated	Conjugated/mixed	Conjugated/mixed
Bilirubin level	≤3 mg/dL	17-50 mg/dL	6-45 mg/dL	<7 mg/dL	<7 mg/dL
Treatment	None	Phototherapy → liver transplant	Phenobarbital	Avoid estrogens	None
Prognosis	Normal	Fatal if untreated	Usually normal	Normal	Normal

Sources: Goldman-Cecil Medicine, p. 1555; Sleisenger & Fordtran's GI and Liver Disease, pp. 336-337; Yamada's Textbook of Gastroenterology; Quick Compendium of Clinical Pathology 5th ed.

This is a shared conversation. Sign in to Orris to start your own chat.